<DOC>
	<DOCNO>NCT01600469</DOCNO>
	<brief_summary>NMDA activation play important role learn memory . NMDA receptor find decrease frontal lobe hippocampus Alzheimer 's disease mild cognitive function impairment . This study randomize , double-blind , placebo-controlled drug trial . All patient allocate randomly 2 group : ( 1 ) NMDA enhancer : DAOI-B group ( start dose : 250-500 mg/d ) ; ( 2 ) placebo group . The study period 24 week . The investigator hypothesize DAOI-B may yield good efficacy placebo cognitive function patient mild cognitive impairment mild Alzheimer 's disease .</brief_summary>
	<brief_title>NMDA-enhancing Agent Treatment Mild Cognitive Impairment Mild Alzheimer 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Cognition Disorders</mesh_term>
	<mesh_term>Mild Cognitive Impairment</mesh_term>
	<criteria>Clinical diagnosis mild cognitive impairment mild Alzheimer 's MMSE 1726 CDR 0.5 1 Hachinski Ischemic Score &gt; 4 substance abuse/dependence Parkinson disease epilepsy major depressive disorder dementia psychotic feature major physical illness severe visual hearing impairment</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>Alzheimer 's disease</keyword>
	<keyword>mild cognitive impairment</keyword>
	<keyword>NMDA</keyword>
</DOC>